TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8727171

Group type: EXPERIMENTAL
Intervention: Besipirdine 5 mg b.i.d.
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Besipirdine 20 mg b.i.d.
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Active treatment (combined besipirdine doses)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Global ratings (Clinician Interview-Based Impression of Change)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Besipirdine
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Post-treatment assessment
Number of subjects: 275
Study: 1744753

Group type: EXPERIMENTAL
Intervention: Educational program consisting of three sessions led by a specially trained RN, focusing on medication compliance, attack prevention, drug effects, relaxation exercises, and smoking cessation.
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group receiving usual medical care and follow-up without the educational program.
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 241
Study: 7064898

Group type: EXPERIMENTAL
Intervention: 400 kcal high quality protein
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 400 kcal low quality protein
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 500 kcal 55 g protein natural food
Number of subjects: 38

Group type: COMPARATOR
Intervention: total fasting with potassium
Number of subjects: 38

Group type: COMPARATOR
Intervention: total fasting without potassium
Number of subjects: 38
Study: 31534032

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Nitrogen oxide (NO)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Normal airways
Number of subjects: 423
Study: 27649903

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mindfulness and Acceptance-based Group Therapy (MAGT)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 137
Study: 27064996

Group type: EXPERIMENTAL
Intervention: Once-daily abacavir + lamivudine
Number of subjects: 669

Group type: COMPARATOR
Intervention: Twice-daily abacavir + lamivudine
Number of subjects: 669
Study: 24736370

Group type: EXPERIMENTAL
Intervention: ITNs + IRS (Indoor Residual Spraying)
Number of subjects: 13146

Group type: COMPARATOR
Intervention: ITNs only
Number of subjects: 13146

Group type: EXPERIMENTAL
Intervention: ITNs + IRS
Number of subjects: 13146
Study: 22079053

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (SMT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 18
Study: 20061012

Group type: EXPERIMENTAL
Intervention: Individual allergens (nAct d 1‐5 and rAct d 8‐9)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Commercial extract
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of Act d 1, Act d 2, Act d 4, and Act d 5
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Exclusion of rAct d 8 and rAct d 9 from allergen panel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Act d 1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: rAct d 8
Number of subjects: 45
Study: 18005841

Group type: EXPERIMENTAL
Intervention: Atropine sulphate premedication (600 microg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No premedication (control)
Number of subjects: 51
Study: 16224378

Group type: EXPERIMENTAL
Intervention: Amelogenins and autologous bone graft
Number of subjects: 2

Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 2
Study: 11821078

Group type: EXPERIMENTAL
Intervention: r‐hFSH 50 IU
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: r‐hFSH 100 IU
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 45
Study: 10025747

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 1364129

Group type: EXPERIMENTAL
Intervention: Beta-carotene (BC) supplementation
Number of subjects: 0
Study: 3947525

Group type: EXPERIMENTAL
Intervention: Salbutamol nebulized at 4 litres/min (1 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Salbutamol nebulized at 8 litres/min (5 mg)
Number of subjects: 40
Study: 30392753

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Botulinum Toxin Type A (BoNT‐A)
Number of subjects: 42
Study: 27266885

Group type: EXPERIMENTAL
Intervention: Thrust manipulation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Joint mobilization
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 25415250

Group type: EXPERIMENTAL
Intervention: Antibiotics (500 mg metronidazole plus 375 mg amoxicillin three times per day for 7 days) during the first, non‐surgical phase of periodontal therapy (T1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo during the first, non‐surgical phase of periodontal therapy (T1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Antibiotics during the second, surgical phase of periodontal therapy (T2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo during the second, surgical phase of periodontal therapy (T2)
Number of subjects: 80
Study: 23498850

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg tablet every 6 months)
Number of subjects: 2589

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2589
Study: 21255511

Group type: EXPERIMENTAL
Intervention: O(2) Flow Regulator
Number of subjects: 18

Group type: COMPARATOR
Intervention: Manual titration by respiratory therapist
Number of subjects: 18
Study: 18245541

Group type: EXPERIMENTAL
Intervention: E75 vaccine (HER2/neu 369-377) + granulocyte macrophage colony-stimulating factor, given intradermally to previously treated, disease-free NP breast cancer patients.
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (non-HLA-A2 and non-HLA-A3 patients) followed prospectively.
Number of subjects: 186
Study: 16476069

Group type: EXPERIMENTAL
Intervention: Mitogenic bovine whey extract (2.5 mg/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitogenic bovine whey extract (10.0 mg/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitogenic bovine whey extract (various concentrations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16736996

Group type: EXPERIMENTAL
Intervention: Chinapril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 20
Study: 10835071

Group type: EXPERIMENTAL
Intervention: DHA-supplemented formula
Number of subjects: 9

Group type: COMPARATOR
Intervention: DHA-free formula
Number of subjects: 9
Study: 9792996

Group type: EXPERIMENTAL
Intervention: Gastrin infusion at 5 pmol kg‐1 h
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Gastrin infusion at 15 pmol kg‐1 h
Number of subjects: 7

Group type: COMPARATOR
Intervention: Basal acid output
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low-dose gastrin stimulated acid output
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-dose gastrin stimulated acid output
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Plasma PP levels during gastrin‐17 infusion
Number of subjects: 7
Study: 7931379

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study: 3144329

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg or 100 mg twice daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg or 240 mg twice daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Metoprolol and Verapamil
Number of subjects: 39
Study: 31210596

Group type: EXPERIMENTAL
Intervention: Text message-based educational intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study: 30475967

Group type: EXPERIMENTAL
Intervention: Nut group (60 g of a mixture of nuts/d)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (avoiding nuts)
Number of subjects: 119
Study: 28112077

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol (600 mg/d)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Plant sterols (2 g/d)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 49
Study: 26072451

Group type: EXPERIMENTAL
Intervention: Multiple Context Exposure in VR
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Multiple Stimuli Condition
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combined Multiple Stimuli and Contexts Condition
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Single Context with Multiple Stimuli
Number of subjects: 58
Study: 22705829

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 30° inclined lateral position
Number of subjects: 32
Study: 19748277

Group type: EXPERIMENTAL
Intervention: Pre-incisional lidocaine with epinephrine infiltration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 18
Study: 19469266

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 105
Study: 16780670

Group type: EXPERIMENTAL
Intervention: Nimodipine for 3 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Basic internal medication (Control)
Number of subjects: 31
Study: 14560325

Group type: EXPERIMENTAL
Intervention: IL-6 and sIL-6R serum levels in patients with AMI and unstable angina
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: IL-10 serum concentration
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Correlation of IL-6 and sIL-6R with acute inflammatory phase parameters and classical risk factors
Number of subjects: 74
Study: 10654017

Group type: EXPERIMENTAL
Intervention: Oral metronidazole; 20 courses (18 empiric)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral vancomycin; 10 courses (8 empiric)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: C. difficile toxin assay
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diarrhea occurrence
Number of subjects: 80
Study: 8774818

Group type: EXPERIMENTAL
Intervention: Rate adaptive pacing (SSIR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fixed rate pacing (SSI)
Number of subjects: 20
Study: 1420042

Group type: EXPERIMENTAL
Intervention: Continuous intravenous propofol infusion
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Continuous intravenous midazolam infusion
Number of subjects: 49

Group type: COMPARATOR
Intervention: No intravenous sedation
Number of subjects: 49
Study: 2864258

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clemastine 3 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Azatadine 3 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Compound score (Hydroxyzine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 24
Study: 30880909

Group type: EXPERIMENTAL
Intervention: Seawater spray (Quinton®) five times daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Carmellose artificial tears eyedrops (Viscofresh® 0.5%) five times a day
Number of subjects: 120
Study: 28776123

Group type: EXPERIMENTAL
Intervention: Nutrition educational intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 27091536

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR) group with 5 hours TIB during manipulation nights
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group with 9 hours TIB during manipulation nights
Number of subjects: 55
Study: 24496490

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) over left or right temporoparietal junction (TPJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimulation over the vertex
Number of subjects: 0
Study: 22985805

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg once daily for a maximum of 28 days
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo once daily for a maximum of 28 days
Number of subjects: 540
Study: 20195400

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 351
Study: 17368663

Group type: EXPERIMENTAL
Intervention: MenC vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenC/MenC challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pnc9-MenC/MnA+C challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenC challenged groups
Number of subjects: 0
Study: 16298658

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg/dose every 14 days for 5 doses (Group I, n = 107)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg/dose every 14 days for 2 doses (Group II, n = 113)
Number of subjects: 298

Group type: COMPARATOR
Intervention: No antibody induction (Group III, n = 78)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: All groups received tacrolimus (TAC), mycophenolate mofetil (MMF), and steroids
Number of subjects: 298
Study: 12042688

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation (3 times per week for 6 months, then 2 times per week for 12 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 31
Study: 10392674

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 28

Group type: COMPARATOR
Intervention: TEA and GA
Number of subjects: 28
Study: 7767531

Group type: EXPERIMENTAL
Intervention: 4% lidocaine (5 cc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (5 cc)
Number of subjects: 0
Study: 2272043

Group type: EXPERIMENTAL
Intervention: 3.0 g/m2 AraC
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 1.0 g/m2 AraC
Number of subjects: 65
Study: 80633

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol (1,25[OH]2D3)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vitamin D3
Number of subjects: 18
Study: 30980389

Group type: EXPERIMENTAL
Intervention: Incredible Years® Teacher Classroom Management (TCM) programme delivered in six whole-day workshops from October to April.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (teachers who did not attend the TCM course).
Number of subjects: 80
Study: 31400337

Group type: EXPERIMENTAL
Intervention: Vasopressin infusion for 24 hours after cardiopulmonary bypass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28731509

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 23
Study: 26317772

Group type: EXPERIMENTAL
Intervention: Insect consumption (entomophagy)
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Insect vendors
Number of subjects: 1059
Study: 22941862

Group type: COMPARATOR
Intervention: Control arm of the RCT (uncircumcised men)
Number of subjects: 966
Study: 21595902

Group type: EXPERIMENTAL
Intervention: Community mobilisation through women's groups and health management committee strengthening
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Community mobilisation and health management committee strengthening
Number of subjects: 43
Study: 19103732

Group type: EXPERIMENTAL
Intervention: High-dose epirubicin with cyclophosphamide (HEC)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Lower dose of epirubicin, 60 mg/m(2) (EC)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Classical oral cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 777
Study: 16384764

Group type: EXPERIMENTAL
Intervention: Whole-body skin examinations
Number of subjects: 16383
Study: 12771114

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate, n = 8506)
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo (n = 8102)
Number of subjects: 16608

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 16608
Study: 10720165

Group type: EXPERIMENTAL
Intervention: Walnut diet (43-57 g/d, 12.5% of energy from walnuts)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reference diet
Number of subjects: 40
Study: 9352475

Group type: EXPERIMENTAL
Intervention: 20 g inositol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8269446

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Zolpidem 40 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3985604

Group type: EXPERIMENTAL
Intervention: Tinidazole (50 mg/kg of body weight to a maximum of 2 g)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Metronidazole (60 mg/kg of body weight to a maximum of 2.4 g)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Metronidazole (50 mg/kg of body weight to a maximum of 2 g daily for 3 days)
Number of subjects: 63
Study: 30907345

Group type: EXPERIMENTAL
Intervention: Psychological and behavioral intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment (psychological and behavioral intervention + biofeedback)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 30276476

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg/day for 3 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Curcumin and Placebo
Number of subjects: 8
Study: 25747467

Group type: EXPERIMENTAL
Intervention: Intermittent exercise (2 bouts of 200kcal each)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous cycling (400kcal)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous running (400kcal)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control session (non-exercise day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Running exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 10
Study: 25441521

Group type: EXPERIMENTAL
Intervention: Electronically amplified stethoscope (Littmann 3200, 3M)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional stethoscope (Littmann Cardiology III; 3M)
Number of subjects: 40
Study: 21935584

Group type: EXPERIMENTAL
Intervention: MMRV vaccine (GlaxoSmithKline Biologicals), 2 doses 42-56 days apart, N=371
Number of subjects: 494

Group type: COMPARATOR
Intervention: MMR + V (Priorix™ and Varilrix™), 1 dose each administered simultaneously, followed by another MMR vaccination 42-56 days later, N=123
Number of subjects: 494
Study: 21144030

Group type: EXPERIMENTAL
Intervention: Coach supervised intervention program targeting jump-landing technique, performed 2 times a week for 3 months during warm-up (5-10 min).
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal training routine (Control group).
Number of subjects: 24
Study: 17604960

Group type: EXPERIMENTAL
Intervention: Low-dose anthracycline treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (32 age-matched normal controls)
Number of subjects: 56
Study: 16139696

Group type: EXPERIMENTAL
Intervention: Mandibular two‐implant overdentures (IOD; n=54)
Number of subjects: 102

Group type: COMPARATOR
Intervention: New mandibular conventional complete dentures (CD; n=48)
Number of subjects: 102
Study: 12474023

Group type: EXPERIMENTAL
Intervention: Atorvastatin Na+
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 10425409

Group type: EXPERIMENTAL
Intervention: 5 mg droperidol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2.5 mg droperidol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7750331

Group type: EXPERIMENTAL
Intervention: Citric acid inhaler (n = 41)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lactose placebo inhaler (n = 59)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Citric acid inhaler (n = 41) with strong airway sensations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups at 6 months
Number of subjects: 100
Study: 2274996

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 0
Study: 7357254

Group type: EXPERIMENTAL
Intervention: Walking at 4 km/h for 1 minute
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Walking at 6 km/h for 1 or 2 minutes
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Walking at 4 km/h for 1 minute on a 10% slope
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: General exercise test
Number of subjects: 26
Study: 30369433

Group type: EXPERIMENTAL
Intervention: 0.5-mg/kg ketamine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 0.2-mg/kg ketamine
Number of subjects: 55

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 55
Study: 26732025

Group type: EXPERIMENTAL
Intervention: Cow's milk fermented with Lactobacillus paracasei CBA L74
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Rice fermented with Lactobacillus paracasei CBA L74
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 377
Study: 25451556

Group type: EXPERIMENTAL
Intervention: n‐3 PUFAs/LC n‐3 PUFAs intake (fish/shellfish, fish oil supplements, perilla oils) for 24 months
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group advised to reduce consumption of fats/oils
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: n‐3 PUFAs/LC n‐3 PUFAs intake
Number of subjects: 205
Study: 24195916

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation plus optimal medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical management alone
Number of subjects: 0
Study: 21455075

Group type: EXPERIMENTAL
Intervention: i-gel device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 60